Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Voyager Therapeutics stock in Canada | $4.2
Own Voyager Therapeutics shares in just a few minutes.
Voyager Therapeutics is a biotechnology business based in the US. Voyager Therapeutics stocks (VYGR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.83 – an increase of 6.6% over the previous week. Voyager Therapeutics employs 177 staff and has a trailing 12-month revenue of around $159.6 million.
How to buy Voyager Therapeutics stock in Canada
- Choose a platform. If you're a beginner, our stock trading table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: VYGR in this case.
- Research Voyager Therapeutics stocks. The platform should provide the latest information available.
- Buy your Voyager Therapeutics stocks. It's that simple.
What's in this guide?
- Can I buy shares in Voyager Therapeutics?
- Has coronavirus impacted Voyager Therapeutics shares?
- Voyager Therapeutics shares summary
- Compare share dealing platforms
- Is Voyager Therapeutics stock a buy or sell?
- Voyager Therapeutics performance over time
- Can I short Voyager Therapeutics shares?
- Are Voyager Therapeutics shares over-valued?
- Voyager Therapeutics's financials
- How volatile are Voyager Therapeutics shares?
- Does Voyager Therapeutics pay a dividend?
- Other common questions
How has Coronavirus impacted Voyager Therapeutics's stock price?
Since the stock market crash in March caused by coronavirus, Voyager Therapeutics's stock price has had significant negative movement.
Its last market close was $4.2, which is 67.01% down on its pre-crash value of $12.73 and 49.05% down on the lowest point reached during the March crash when the stocks fell as low as $6.26.
If you had bought $1,000 worth of Voyager Therapeutics stocks at the start of February 2020, those stocks would have been worth $614.49 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $357.46.
Voyager Therapeutics stock priceUse our graph to track the performance of VYGR stocks over time.
Voyager Therapeutics stocks at a glance
|Latest market close||$4.2|
|52-week range||$3.04 - $12.65|
|50-day moving average||$3.9466|
|200-day moving average||$5.2754|
|Wall St. target price||$9.61|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.046|
Compare online stock trading platforms
Note: The dollar amounts in the table below are in Canadian dollars.
Is it a good time to buy Voyager Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Voyager Therapeutics price performance over time
|1 month (2021-07-02)||1.94%|
|3 months (2021-04-30)||-12.86%|
Is Voyager Therapeutics under- or over-valued?
Valuing Voyager Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Voyager Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Voyager Therapeutics's P/E ratio
Voyager Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Voyager Therapeutics stocks trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stocks or simply that they're under-valued.
Voyager Therapeutics's EBITDA
Voyager Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$30.5 million.
The EBITDA is a measure of a Voyager Therapeutics's overall financial performance and is widely used to measure a its profitability.
Voyager Therapeutics financials
|Revenue TTM||USD$159.6 million|
|Operating margin TTM||16.44%|
|Gross profit TTM||USD$62.4 million|
|Return on assets TTM||5.85%|
|Return on equity TTM||36.45%|
|Market capitalisation||USD$118.8 million|
TTM: trailing 12 months
How to short and sell Voyager Therapeutics stocks
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "VYGR.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 887,565 Voyager Therapeutics stocks held short by investors – that's known as Voyager Therapeutics's "short interest". This figure is 1.5% up from 874,329 last month.
There are a few different ways that this level of interest in shorting Voyager Therapeutics stocks can be evaluated.
Voyager Therapeutics's "short interest ratio" (SIR)
Voyager Therapeutics's "short interest ratio" (SIR) is the quantity of Voyager Therapeutics stocks currently shorted divided by the average quantity of Voyager Therapeutics stocks traded daily (recently around 558216.98113208). Voyager Therapeutics's SIR currently stands at 1.59. In other words for every 100,000 Voyager Therapeutics stocks traded daily on the market, roughly 1590 stocks are currently held short.
However Voyager Therapeutics's short interest can also be evaluated against the total number of Voyager Therapeutics stocks, or, against the total number of tradable Voyager Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Voyager Therapeutics's short interest could be expressed as 0.02% of the outstanding stocks (for every 100,000 Voyager Therapeutics stocks in existence, roughly 20 stocks are currently held short) or 0.0398% of the tradable stocks (for every 100,000 tradable Voyager Therapeutics stocks, roughly 40 stocks are currently held short).
Such a low SIR usually points to an optimistic outlook for the stock price, with fewer people currently willing to bet against Voyager Therapeutics.
Find out more about how you can short Voyager Therapeutics stock.
Voyager Therapeutics stock dividends
We're not expecting Voyager Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.
Voyager Therapeutics stock price volatility
Over the last 12 months, Voyager Therapeutics's stocks have ranged in value from as little as $3.04 up to $12.65. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Voyager Therapeutics's is 1.0724. This would suggest that Voyager Therapeutics's stocks are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Voyager Therapeutics overview
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Stocks similar to Voyager Therapeutics
Voyager Therapeutics in the news
Voyager Digital Acquires Leading Global Cryptocurrency Payment Processing Company, Coinify
Voyager Digital Participates in Canaccord Genuity's Global Growth Conference
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Frequently asked questions
More guides on Finder
How to buy Wheels Up (UP) stock in Canada when it goes public
Everything we know about the Wheels Up IPO, plus information on how to buy in.
How to invest $1 million
Here are the top 5 ways you should invest $1 million.
How to buy Brookfield Asset Management Reinsurance Partners Ltd (BAMR) stock in Canada when it goes public
Everything we know about the Brookfield Asset Management Reinsurance Partners Ltd IPO, plus information on how to buy in.
How to buy Traeger (COOK) stock in Canada when it goes public
Everything we know about the Traeger IPO, plus information on how to buy in.
How to buy Teads (TEAD) stock in Canada when it goes public
Everything we know about the Teads IPO, plus information on how to buy in.
How to buy Snap One Holdings Corp (SNPO) stock in Canada
Everything we know about the Snap One Holdings Corp IPO, plus information on how to buy in.
How to buy Riskified (RSKD) stock in Canada
Everything we know about the Riskified IPO, plus information on how to buy in.
How to buy Preston Hollow Community Capital (PHCC) stock in Canada when it goes public
Everything we know about the Preston Hollow Community Capital IPO, plus information on how to buy in.
How to buy PowerSchool Holdings (PWSC) stock in Canada
Everything we know about the PowerSchool Holdings IPO, plus information on how to buy in.
How to buy MeridianLink (MLNK) stock in Canada
Everything we know about the MeridianLink IPO, plus information on how to buy in.